Publication: Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac
dc.contributor.author | Sudha, Thangirala | |
dc.contributor.author | Bharali, Dhruba J | |
dc.contributor.author | Darwish, Noureldien H.E. | |
dc.contributor.author | Keating, Kelly A | |
dc.contributor.author | Lin, Hung-Yun | |
dc.contributor.author | Davis, Paul J. | |
dc.contributor.author | Mousa, Shaker A | |
dc.contributor.buuauthor | Yalçın, Murat | |
dc.contributor.buuauthor | Coşkun, Melis Debreli | |
dc.contributor.department | Veteriner Fakültesi | |
dc.contributor.department | Fen Edebiyat Fakültesi | |
dc.contributor.department | Biyoloji Bölümü | |
dc.contributor.department | Fizyoloji Ana Bilim Dalı | |
dc.contributor.orcid | 0000-0002-5600-8162 | |
dc.contributor.researcherid | AAG-6956-2021 | |
dc.contributor.researcherid | AAF-3992-2020 | |
dc.contributor.scopusid | 57192959734 | |
dc.contributor.scopusid | 57193066146 | |
dc.date.accessioned | 2022-11-04T06:26:08Z | |
dc.date.available | 2022-11-04T06:26:08Z | |
dc.date.issued | 2017-02 | |
dc.description.abstract | Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin alpha v beta 3; alpha v beta 3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy. | |
dc.description.sponsorship | NanoPharmaceuticals LLC (NY, USA) | |
dc.description.sponsorship | NanoPharmaceuticals LLC | |
dc.identifier.citation | Sudha, T. vd. (2017). ''Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac''. Nanomedicine, 12(3), 195-205. | |
dc.identifier.endpage | 205 | |
dc.identifier.issn | 1743-5889 | |
dc.identifier.issn | 1748-6963 | |
dc.identifier.issue | 3 | |
dc.identifier.pubmed | 28102776 | |
dc.identifier.scopus | 2-s2.0-85010383217 | |
dc.identifier.startpage | 195 | |
dc.identifier.uri | https://doi.org/10.2217/nnm-2016-0315 | |
dc.identifier.uri | https://www.futuremedicine.com/doi/10.2217/nnm-2016-0315 | |
dc.identifier.uri | http://hdl.handle.net/11452/29376 | |
dc.identifier.volume | 12 | |
dc.identifier.wos | 000395674900006 | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | Future Medicine | |
dc.relation.collaboration | Yurt dışı | |
dc.relation.journal | Nanomedicine | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Biotechnology & applied microbiology | |
dc.subject | Science & technology - other topics | |
dc.subject | Cisplatin | |
dc.subject | Integrin | |
dc.subject | Nanotetrac | |
dc.subject | NDAT | |
dc.subject | Tetraiodothyroacetic acid | |
dc.subject | Urinary bladder carcinoma | |
dc.subject | Activated protein-kinase | |
dc.subject | Tetraiodothyroacetic acid | |
dc.subject | Thyroid-hormone | |
dc.subject | Cancer-cells | |
dc.subject | Platinum | |
dc.subject | Integrin | |
dc.subject | Receptor | |
dc.subject | Growth | |
dc.subject | Drugs | |
dc.subject.emtree | Acetic acid derivative | |
dc.subject.emtree | Cisplatin | |
dc.subject.emtree | Nanocarrier | |
dc.subject.emtree | Nanodiaminotetrac | |
dc.subject.emtree | Nanoparticle | |
dc.subject.emtree | Polyglactin | |
dc.subject.emtree | Tetraiodothyroacetic acid | |
dc.subject.emtree | Unclassified drug | |
dc.subject.emtree | Antineoplastic agent | |
dc.subject.emtree | Lactic acid | |
dc.subject.emtree | Polyglycolic acid | |
dc.subject.emtree | Polylactic acid-polyglycolic acid copolymer | |
dc.subject.emtree | Vitronectin receptor | |
dc.subject.emtree | Animal experiment | |
dc.subject.emtree | Animal model | |
dc.subject.emtree | Animal tissue | |
dc.subject.emtree | Article | |
dc.subject.emtree | Bladder cancer | |
dc.subject.emtree | Cancer size | |
dc.subject.emtree | Controlled study | |
dc.subject.emtree | Covalent bond | |
dc.subject.emtree | Drug delivery system | |
dc.subject.emtree | Drug dosage form comparison | |
dc.subject.emtree | Drug efficacy | |
dc.subject.emtree | Drug response | |
dc.subject.emtree | Drug tissue level | |
dc.subject.emtree | Female | |
dc.subject.emtree | Human | |
dc.subject.emtree | Human cell | |
dc.subject.emtree | Mouse | |
dc.subject.emtree | Nanoencapsulation | |
dc.subject.emtree | Nonhuman | |
dc.subject.emtree | Tumor xenograft | |
dc.subject.emtree | Animal | |
dc.subject.emtree | Bladder tumor | |
dc.subject.emtree | Cancer transplantation | |
dc.subject.emtree | Cell culture technique | |
dc.subject.emtree | Cell survival | |
dc.subject.emtree | Chemistry | |
dc.subject.emtree | Drug delivery system | |
dc.subject.emtree | Drug release | |
dc.subject.emtree | Metabolism | |
dc.subject.emtree | Nude mouse | |
dc.subject.emtree | Particle size | |
dc.subject.emtree | Surface property | |
dc.subject.emtree | Tumor cell line | |
dc.subject.emtree | Xenograft | |
dc.subject.emtree | Cisplatin | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antineoplastic agents | |
dc.subject.mesh | Cell culture techniques | |
dc.subject.mesh | Cell line | |
dc.subject.mesh | Tumor | |
dc.subject.mesh | Cell survival | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Drug delivery systems | |
dc.subject.mesh | Drug liberation | |
dc.subject.mesh | Female | |
dc.subject.mesh | Heterografts | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Integrin alphabeta3 | |
dc.subject.mesh | Lactic acid | |
dc.subject.mesh | Mice, nude | |
dc.subject.mesh | Nanoparticles | |
dc.subject.mesh | Neoplasm transplantation | |
dc.subject.mesh | Particle size | |
dc.subject.mesh | Polyglycolic acid | |
dc.subject.mesh | Surface properties | |
dc.subject.mesh | Urinary bladder neoplasms | |
dc.subject.scopus | Integrin; Thyroid Hormones; Nano-Diamino-Tetrac | |
dc.subject.wos | Biotechnology & applied microbiology | |
dc.subject.wos | Nanoscience & nanotechnology | |
dc.title | Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac | |
dc.type | Article | |
dc.wos.quartile | Q1 (Biotechnology & applied microbiology) | |
dc.wos.quartile | Q2 (Nanoscience & nanotechnology) | |
dspace.entity.type | Publication | |
local.contributor.department | Veteriner Fakültesi/Fizyoloji Ana Bilim Dalı | |
local.contributor.department | Fen Edebiyat Fakültesi/Biyoloji Bölümü | |
local.indexed.at | Scopus | |
local.indexed.at | WOS |